As a world-leading drug delivery device solutions and combination product services partner, Nemera’s purpose of putting patients first enables the design and manufacture of devices that maximize treatment efficacy. Nemera is committed to the highest quality standards, from early device strategy to state-of-the-art manufacturing. Agile and open-minded, Nemera works closely with customers to ensure the success of their combination products.

For more information please visit https://atombioworks.com/

Vitranu is a biotech company developing sustained-release drug delivery for ophthalmology. Its core technology, the Tunable Extended Release Microcapsule, enables months-long, controlled release of biologics and sensitive molecules without harmful processing. This platform addresses the leading unmet need in retinal care—durable therapy—while reducing injection frequency and improving patient outcomes.

BioLogic Pharma Solutions was founded in 2024 to solve a persistent challenge in the biotech and pharmaceutical industries: how to advance life-changing therapies efficiently and effectively without the high overhead of traditional full-time Medical Affairs teams. With deep expertise in rare disease, neurology, and radiopharmaceuticals, Founder Mary Hames, PhD, MBA saw a critical need for flexible, high-impact Medical Affairs support that could scale with the needs of innovative companies. 

BioLogic’s solution is its "Fractional Medical Affairs" model, an agile, project-based approach that allows clients to tap into senior-level expertise for strategic planning, trial recruitment, and key opinion leader (KOL) engagement. This model empowers companies to remain lean while accelerating development timelines and enhancing commercial readiness.For more information, please visit https://biologicpharmasolutions.com/

Manifold Bio has built the first high-throughput in vivo (HTV) discovery engine—combining massively multiplexed in vivo screening and AI-powered design to create targeted biologics.

For more information please visit https://www.aperya.com/

Akyso Therapeutics is developing next-generation, long-acting subcutaneous implants for opioid use disorder and other chronic conditions. Our biodegradable polymer platform delivers extended, steady-state drug release, improving adherence, outcomes, and patient quality of life while reducing healthcare burden.

Transdermal Specialties Global is committed to developing innovative drug delivery systems that enhance health and improve the quality of life. We are a pioneer in ultrasonic active patch delivery systems. The first is a painless patented transdermal insulin delivery patch system using ultrasound frequencies that delivers insulin into the bloodstream.

For more information please visit https://www.7hillspharma.com/